Teva to Produce Generic Drug for Attention Deficit and Hyperactivity Disorder

Shire Plc (SHP) has settled a patent lawsuit against Teva Pharmaceutical Industries Ltd. (TEVA). This paves the way for lower-cost generic versions of Intuniv, used to treat attention deficit hyperactivity disorder (ADHD).
Israel based Teva is the world’s largest generic-drug company. According to a statement from Shire, Teva will market a generic version of the Intuniv under license. The license will take effect once another generic-drug maker, Actavis Inc. (ACT), has sold the drug for six months starting in December 2014.
Shire sued Teva, based in Petach Tikva, Israel, in federal court in Wilmington, Delaware, in April 2010 alleging infringement of two patents for Intuniv. Shire previously settled with Parsippany, New Jersey-based Actavis over the patents. A trial of the litigation against Teva and Actavis was held in September.
The case is Shire LLC v. Teva Pharmaceuticals USA Inc., 10-cv-00329, U.S. District Court, District of Delaware (Wilmington).

Categories: Intellectual Property, Patents, pharmaceuticals, pharmaceuticals and Biotechnology, Teva

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: